Ankylosing spondylitis (AS) is a chronic immune‐mediated disease marked by sustained joint inflammation and aberrant bone remodelling. Although chronic antigen exposure usually enforces terminal exhaustion, emerging evidence indicates that a subset of CD8 + T cells in AS evades canonical exhaustion programmes while expressing programmed cell death protein 1 (PD‐1). These exhaustion‐resistant cells retain effector function and likely contribute to persistent tissue inflammation and structural damage. In this review, we dissect the cellular and molecular basis of exhaustion resistance in AS CD8 + T cells and focus on the convergence of intermittent T cell receptor (TCR) stimulation, metabolic adaptation that preserves mitochondrial fitness, and co‐stimulatory inputs from interleukin‐15 (IL‐15) and CD28. We propose an integrated three‐axis model governing CD8 + T cell fate and functional persistence in the AS context shaped by human leukocyte antigen‐B27 (HLA‐B27) and the gut–joint axis. Clarifying these mechanisms refines current views of T cell dysfunction in chronic inflammation and highlights therapeutic strategies aimed at reprogramming pathogenic immunity in AS.
The gut-bone axis is pivotal in the pathogenesis of ankylosing spondylitis (AS), with gut dysbiosis and mucosal immune activation driving skeletal pathology. However, translating these mechanistic insights into effective therapies remains challenging. This review critically analyzes this translational gap, arguing that the therapeutic paradoxes seen with cytokine inhibitors and microbiome-targeted therapies are a direct consequence of the disease's significant variability. We focus on the unexpected failure of IL-23 inhibitors and the dual effects of IL-17 blockade to illustrate the need for a nuanced understanding of tissue-specific immunity. We then propose a biomarker-driven, AI-assisted therapeutic framework that integrates multi-omic data to personalize AS treatment, aiming to bridge the gap between mechanistic insights and clinical success and offer a path toward progression-free remission.
Rheumatoid arthritis (RA) is associated with a high rate of hepatitis B virus (HBV) infection. A large proportion of HBV reactivation may occur in RA patients after immunosuppression treatment, while fulminant hepatitis may occur in severe cases. Immunosuppressants are fundamental medications for the treatment of RA but carry the risk of inducing HBV reactivation. This inherent contradiction poses challenges throughout the immunosuppressive treatment process in patients with RA. Recently, numerous studies have been conducted on the contradictory therapeutic mechanisms between RA treatment and HBV infection, including aspects of innate immunity, adaptive immunity, and related signalling pathways. In this article, we review the immunological mechanisms underlying the onset of RA and HBV infections, providing a reference for determining appropriate treatment plans to reduce therapeutic contradictions and thereby reduce the risk of HBV reactivation in patients with RA combined with HBV infection.